BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives $129.56 Consensus PT from Brokerages

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has been given an average rating of “Moderate Buy” by the nineteen analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $129.5625.

A number of equities analysts recently issued reports on the stock. Jefferies Financial Group reiterated a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. Wall Street Zen cut shares of BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, May 23rd. Bank of America reiterated a “buy” rating and set a $128.00 price objective on shares of BioNTech in a research report on Tuesday, March 10th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of BioNTech in a research note on Tuesday, March 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a research note on Wednesday, April 8th.

BioNTech Stock Up 3.3%

BioNTech stock opened at $94.26 on Thursday. BioNTech has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The firm has a market capitalization of $23.84 billion, a PE ratio of -16.03 and a beta of 1.33. The company’s 50-day moving average is $93.80 and its 200-day moving average is $97.91. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.80 and a quick ratio of 8.74.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. The company had revenue of $1.06 billion during the quarter. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. Sell-side analysts anticipate that BioNTech will post -5.67 earnings per share for the current year.

BioNTech declared that its board has authorized a share repurchase plan on Thursday, May 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 4.2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of BioNTech stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total value of $5,528,000.00. Following the sale, the chief operating officer owned 399,387 shares of the company’s stock, valued at approximately $44,156,226.72. The trade was a 11.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 19.20% of the company’s stock.

Hedge Funds Weigh In On BioNTech

Hedge funds have recently bought and sold shares of the company. Larson Financial Group LLC lifted its position in BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares during the last quarter. EFG International AG bought a new stake in BioNTech during the 4th quarter valued at $29,000. Caitong International Asset Management Co. Ltd raised its holdings in BioNTech by 520.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after buying an additional 260 shares during the last quarter. Huntington National Bank raised its holdings in BioNTech by 1,266.7% during the 3rd quarter. Huntington National Bank now owns 410 shares of the company’s stock valued at $40,000 after buying an additional 380 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in BioNTech by 118.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after purchasing an additional 305 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.